{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:33:51Z","timestamp":1787585631594,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Joint Fund for Innovation and Development of Natural Science of Hubei Province","award":["2025AFD824"],"award-info":[{"award-number":["2025AFD824"]}]},{"name":"he National High Technology Research and Development Program of China","award":["2021YFA1101504"],"award-info":[{"award-number":["2021YFA1101504"]}]},{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2022BCA017"],"award-info":[{"award-number":["2022BCA017"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11596-026-00218-4","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:44Z","timestamp":1783333004000},"page":"867-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances and Clinical Applications of Thrombopoietic Agents"],"prefix":"10.1007","volume":"46","author":[{"given":"Jin-huan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"7","key":"218_CR1","first-page":"498","volume":"59","author":"JX Wang","year":"2020","unstructured":"Chinese Society of Internal Medicine, Chinese Medical Association; Wang JX, Zhang FC, Liu XQ, et al. Expert consensus on the diagnosis and management of thrombocytopenia in China. Zhonghua Nei Ke Za Zhi (Chinese). 2020;59(7):498\u2013510.","journal-title":"Zhonghua Nei Ke Za Zhi (Chinese)"},{"issue":"2","key":"218_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.55460\/333T-XIYF","volume":"22","author":"KS Nietsch","year":"2022","unstructured":"Nietsch KS, Roach TM, Wilson ZD, et al. Principles and considerations in the early identification and prehospital treatment of thrombocytopenia. J Spec Oper Med. 2022;22(2):75\u201379.","journal-title":"J Spec Oper Med."},{"key":"218_CR3","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult primary immune thrombocytopenia (2020 edition). Zhonghua Xueyexue Zazhi (Chinese). 2020;41(8):617\u2013623."},{"issue":"1","key":"218_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","volume":"22","author":"G Soff","year":"2024","unstructured":"Soff G, Leader A, Al-Samkari H, et al. Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024;22(1):53\u201360.","journal-title":"J Thromb Haemost."},{"issue":"1","key":"218_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","volume":"98","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10\u201323.","journal-title":"Int J Hematol."},{"key":"218_CR6","unstructured":"Chinese Society of Clinical Oncology (CSCO) Anti-Lymphoma Alliance, CSCO Anti-Leukemia Alliance, CSCO Expert Committee on the Safety Management of Antitumor Drugs (ASMC) Group. Chinese Expert Consensus on the Clinical Application of Recombinant Human Interleukin-11 in the Prevention and Treatment of Thrombocytopenia (2021 Edition). Chin Clin Oncol (Chinese). 2020;25(12):1129\u20131137."},{"key":"218_CR7","doi-asserted-by":"publisher","first-page":"1531824","DOI":"10.3389\/fmed.2025.1531824","volume":"12","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhang N, Jiang T, et al. Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data. Front Med. 2025;12:1531824.","journal-title":"Front Med."},{"issue":"11","key":"218_CR8","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/ajh.70052","volume":"100","author":"C Marques","year":"2025","unstructured":"Marques C, Moulis G, Roussotte M, et al. Efficacy and thrombotic risk of thrombopoietin receptor agonists for immune thrombocytopenia secondary to systemic lupus and antiphospholipid syndrome: French experience with 80 patients. Am J Hematol. 2025;100(11):1972\u20131982.","journal-title":"Am J Hematol."},{"key":"218_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103581","volume":"171","author":"M Tjepkema","year":"2022","unstructured":"Tjepkema M, Amini S, Schipperus M. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;171:103581.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"5","key":"218_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3324\/haematol.2013.098921","volume":"99","author":"W Ghanima","year":"2014","unstructured":"Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937\u2013944.","journal-title":"Haematologica."},{"issue":"6","key":"218_CR11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood.V87.6.2154.bloodjournal8762154","volume":"87","author":"PJ Fielder","year":"1996","unstructured":"Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 1996;87(6):2154\u20132161.","journal-title":"Blood."},{"issue":"12","key":"218_CR12","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI26674","volume":"115","author":"K Kaushansky","year":"2005","unstructured":"Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339\u20133347.","journal-title":"J Clin Invest."},{"issue":"5","key":"218_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.5114\/aoms\/141134","volume":"17","author":"Q Li","year":"2021","unstructured":"Li Q, Jin G, Jiang C, et al. Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia. Arch Med Sci. 2021;17(5):1440\u20131446.","journal-title":"Arch Med Sci."},{"issue":"12","key":"218_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","volume":"101","author":"CA Di Buduo","year":"2016","unstructured":"Di Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag\u2019s promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation. Haematologica. 2016;101(12):1479\u20131488.","journal-title":"Haematologica."},{"issue":"16","key":"218_CR15","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81(16):1905\u20131913.","journal-title":"Drugs."},{"key":"218_CR16","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, Soff G, Balduzzi A, et al. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther. 2021;15:2243\u20132268.","journal-title":"Drug Des Devel Ther."},{"key":"218_CR17","doi-asserted-by":"publisher","first-page":"204062072311527","DOI":"10.1177\/20406207231152746","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang L, Xu J, Zhang H, et al. Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia. Ther Adv Hematol. 2023;14:20406207231152746.","journal-title":"Ther Adv Hematol."},{"key":"218_CR18","doi-asserted-by":"crossref","unstructured":"Zhang X, Chuai Y, Nie W, et al. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev. 2017;2017(11):CD012035.","DOI":"10.1002\/14651858.CD012035.pub2"},{"key":"218_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103459","volume":"87","author":"Y Chen","year":"2025","unstructured":"Chen Y, Sun T, Gao D, et al. Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine. 2025;87:103459.","journal-title":"EClinicalMedicine."},{"issue":"6","key":"218_CR20","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1111\/bjh.19761","volume":"205","author":"J Ma","year":"2024","unstructured":"Ma J, Zhang X, Zhao L, et al. Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double-blind, placebo-controlled phase III trial.\u00a0Br J Haematol. 2024;205(6):2403\u20132413.","journal-title":"Br J Haematol."},{"key":"218_CR21","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2024-206420","volume":"144","author":"C Jiao","year":"2024","unstructured":"Jiao C, Cui J, Zhou J, et al. Efficacy analysis of rhtpo and construction of recovery prediction model in acute myeloid leukemia patients with post-chemotherapy thrombocytopenia. Blood. 2024;144:4250.","journal-title":"Blood."},{"key":"218_CR22","unstructured":"Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance, CSCO Anti-Lymphoma Alliance. Chinese expert consensus on the diagnosis and treatment of chemotherapy-induced thrombocytopenia with acute leukemia. Leuk Lymph (Chinese). 2019;28(4):193\u2013197."},{"key":"218_CR23","unstructured":"Han YF, Xu XY, Yu YY, et al. Efficacy and safety of recombinant human thrombopietin injection\u00a0in patients with chronic liver disease-related thrombocytopenia scheduled for invasive surgery: a multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Presented at The 76th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7\u201311, 2025; Washington, DC, USA. Abstract."},{"issue":"2","key":"218_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/bjh.19954","volume":"206","author":"D Feng","year":"2025","unstructured":"Feng D, Liu Q, Gao H, et al. Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: a NICHE cohort study. Br J Haematol. 2025;206(2):769\u2013772.","journal-title":"Br J Haematol."},{"key":"218_CR25","unstructured":"Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the management of bleeding complications after hematopoietic stem cell transplantation (2021). Chin J Hematol (Chinese). 2021;42(4):276\u2013280."},{"issue":"9763","key":"218_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393\u2013402.","journal-title":"Lancet."},{"issue":"23","key":"218_CR27","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527\u20132536.","journal-title":"Blood."},{"issue":"8","key":"218_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044885","volume":"11","author":"KA Shimano","year":"2021","unstructured":"Shimano KA, Grace RF, Despotovic JM, et al. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021;11(8):e044885.","journal-title":"BMJ Open."},{"issue":"20","key":"218_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1001\/jama.2025.18168","volume":"334","author":"KA Shimano","year":"2025","unstructured":"Shimano KA, Grimes AB, Kaicker S, et al. Eltrombopag for newly diagnosed pediatric immune thrombocytopenia requiring treatment: the PINES randomized clinical trial. JAMA. 2025;334(20):1816\u20131826.","journal-title":"JAMA."},{"issue":"1","key":"218_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"218_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41375-024-02450-0","volume":"39","author":"B Yang","year":"2025","unstructured":"Yang B, Wang L, Fu L, et al. Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients. Leukemia. 2025;39(1):261\u2013264.","journal-title":"Leukemia."},{"issue":"9","key":"218_CR32","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1007\/s00277-024-05910-w","volume":"103","author":"X Li","year":"2024","unstructured":"Li X, Shangguan X, Wang H, et al. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence. Ann Hematol. 2024;103(9):3483\u20133491.","journal-title":"Ann Hematol."},{"issue":"2","key":"218_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","volume":"146","author":"NH Afdhal","year":"2014","unstructured":"Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442\u2013452.e1.","journal-title":"Gastroenterology."},{"issue":"6","key":"218_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","volume":"106","author":"ES Winer","year":"2017","unstructured":"Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017;106(6):765\u2013776.","journal-title":"Int J Hematol."},{"issue":"1","key":"218_CR35","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","volume":"5","author":"M Mittelman","year":"2018","unstructured":"Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34\u2013e43.","journal-title":"Lancet Haematol."},{"issue":"11","key":"218_CR36","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","volume":"106","author":"M Shoukier","year":"2021","unstructured":"Shoukier M, Borthakur G, Jabbour E, et al. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021;106(11):2853\u20132858.","journal-title":"Haematologica."},{"issue":"1","key":"218_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37.","journal-title":"J Hematol Oncol."},{"key":"218_CR38","doi-asserted-by":"publisher","first-page":"204062072210851","DOI":"10.1177\/20406207221085197","volume":"13","author":"G Peng","year":"2022","unstructured":"Peng G, He G, Chang H, et al. A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Ther Adv Hematol. 2022;13:20406207221085197.","journal-title":"Ther Adv Hematol."},{"key":"218_CR39","unstructured":"Red Blood Cell Diseases (Anemia), Group of Chinese Society of Hematology, Chinese Medical Association. Guidelines for the diagnosis and treatment of aplastic anemia in China (2022). Chin J Hematol (Chinese). 2022;43(11):881\u2013888."},{"key":"218_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2024-206377","volume":"144","author":"F Zhang","year":"2024","unstructured":"Zhang F, Zhao X, Chang H, et al. Hetrombopag added to immunosuppressive therapy in first-line treatment of severe aplastic anemia: a randomized, double-blind, placebo-controlled phase 3 trial. Blood. 2024;144:304.","journal-title":"Blood."},{"key":"218_CR41","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1182\/blood-2025-4804","volume":"146","author":"R Wu","year":"2025","unstructured":"Wu R, Gao J, Liu Y, et al. Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial. Blood. 2025;146:4804.","journal-title":"Blood."},{"issue":"Suppl 1","key":"218_CR42","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1182\/blood-2025-4812","volume":"146","author":"H Mei","year":"2025","unstructured":"Mei H, Liu X, Li Y, et al. Hetrombopag for patients with persistent primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III Trial. Blood. 2025;146(Suppl 1):4812.","journal-title":"Blood."},{"key":"218_CR43","doi-asserted-by":"publisher","first-page":"175883592412609","DOI":"10.1177\/17588359241260985","volume":"16","author":"S Qin","year":"2024","unstructured":"Qin S, Wang Y, Yao J, et al. Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study. Ther Adv Med Oncol. 2024;16:17588359241260985.","journal-title":"Ther Adv Med Oncol."},{"key":"218_CR44","unstructured":"Chinese Society of Clinical Oncology, Chemotherapy Committee; Chinese Society of Clinical Oncology, Supportive Care Committee. Expert consensus on the diagnosis and treatment of cancer therapy\u2013related thrombocytopenia in China (2023 edition). Natl Med J China, 2023,103(33):2579\u20132590."},{"issue":"Suppl 1","key":"218_CR45","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2025-1256","volume":"146","author":"SK Qin","year":"2025","unstructured":"Qin SK,\u00a0Zhang YQ,\u00a0Li HL, et al. Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial.\u00a0Blood.\u00a02025;146(Supple 1):1256.","journal-title":"Blood"},{"issue":"3","key":"218_CR46","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","volume":"155","author":"N Terrault","year":"2018","unstructured":"Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705\u2013718.","journal-title":"Gastroenterology."},{"issue":"6","key":"218_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102158","volume":"7","author":"H Mei","year":"2023","unstructured":"Mei H, Zhou H, Hou M, et al. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Res Pract Thromb Haemost. 2023;7(6):102158.","journal-title":"Res Pract Thromb Haemost."},{"issue":"7","key":"218_CR48","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1016\/S2352-3026(25)00107-3","volume":"12","author":"RF Grace","year":"2025","unstructured":"Grace RF, Leblebisatan G, Aydinok Y, et al. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025;12(7):e494\u2013e504.","journal-title":"Lancet Haematol."},{"key":"218_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-025-01328-3","volume":"15","author":"L Wang","year":"2025","unstructured":"Wang L, Ye L, Zhao X, et al. Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study. Blood Cancer J. 2025;15:119.","journal-title":"Blood Cancer J."},{"issue":"3","key":"218_CR50","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","volume":"9","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Kolb-Sielecki J, Safina SZ, et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022;9(3):e179\u2013e189.","journal-title":"Lancet Haematol."},{"issue":"6","key":"218_CR51","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","volume":"17","author":"H Hidaka","year":"2019","unstructured":"Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192\u20131200.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"218_CR52","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.30561","volume":"70","author":"M Peck-Radosavljevic","year":"2019","unstructured":"Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336\u20131348.","journal-title":"Hepatology."},{"issue":"1","key":"218_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12072-022-10421-9","volume":"17","author":"Z Ding","year":"2023","unstructured":"Ding Z, Wu H, Zeng Y, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures. Hepatol Int. 2023;17(1):180\u2013189.","journal-title":"Hepatol Int."},{"issue":"6","key":"218_CR54","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/HEP.0000000000000671","volume":"79","author":"CJ Karvellas","year":"2024","unstructured":"Karvellas CJ, Bajaj JS, Kamath PS, et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology. 2024;79(6):1463\u20131502.","journal-title":"Hepatology."},{"issue":"4","key":"218_CR55","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2478\/jtim-2023-0106","volume":"11","author":"H Zhou","year":"2023","unstructured":"Zhou H, Han S, Jin J, et al. Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Transl Int Med. 2023;11(4):423\u2013432.","journal-title":"J Transl Int Med."},{"issue":"3","key":"218_CR56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjh.12260","volume":"161","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411\u2013423.","journal-title":"Br J Haematol."},{"issue":"11","key":"218_CR57","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3324\/haematol.2018.202283","volume":"104","author":"MD Tarantino","year":"2019","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, et al. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica. 2019;104(11):2283\u20132291.","journal-title":"Haematologica."},{"issue":"11","key":"218_CR58","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","volume":"6","author":"JW Lee","year":"2019","unstructured":"Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562\u2013e572.","journal-title":"Lancet Haematol."},{"issue":"16_suppl","key":"218_CR59","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1200\/JCO.2025.43.16_suppl.12007","volume":"43","author":"H Al-Samkari","year":"2025","unstructured":"Al-Samkari H, Munoz C, Geredeli C, et al. Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: a global, phase 3, randomized, placebo-controlled trial (RCT). J Clin Oncol. 2025;43(16_suppl):12007.","journal-title":"J Clin Oncol"},{"key":"218_CR60","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors (Version 3, 2024) [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2024 Jan 30. Available from:\u00a0https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1454."},{"issue":"5","key":"218_CR61","first-page":"621","volume":"30","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Geyer JT, Lee CS, et al. Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. Platelets. 2019;30(5):621\u2013628","journal-title":"Platelets."},{"issue":"7","key":"218_CR62","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921\u2013930.","journal-title":"Am J Hematol."},{"issue":"6","key":"218_CR63","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2024024250","volume":"144","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2024","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Bermejo-Vega N, Cardesa-Cabrera R, et al. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood. 2024;144(6):646\u2013656.","journal-title":"Blood."},{"issue":"8","key":"218_CR64","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","volume":"11","author":"Y Hu","year":"2024","unstructured":"Hu Y, Liu X, Zhou H, et al. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024;11(8):e567\u2013e579.","journal-title":"Lancet Haematol."},{"key":"218_CR65","doi-asserted-by":"publisher","first-page":"204062072312054","DOI":"10.1177\/20406207231205431","volume":"14","author":"DJ Kuter","year":"2023","unstructured":"Kuter DJ, Bussel JB, Ghanima W, et al. Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. Ther Adv Hematol. 2023;14:20406207231205431.","journal-title":"Ther Adv Hematol."},{"issue":"10413","key":"218_CR66","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","volume":"402","author":"CM Broome","year":"2023","unstructured":"Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10413):1648\u20131659.","journal-title":"Lancet."},{"issue":"2","key":"218_CR67","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/bjh.19858","volume":"206","author":"N Cooper","year":"2025","unstructured":"Cooper N, Bussel JB, Ka\u017amierczak M, et al. Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. Br J Haematol. 2025;206(2):675\u2013688.","journal-title":"Br J Haematol."},{"issue":"11","key":"218_CR68","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1182\/blood.V97.11.3675","volume":"97","author":"S van den Oudenrijn","year":"2001","unstructured":"van den Oudenrijn S, de Haas M, von dem Borne AEGKr. Screening for c-mpl mutations in patients with congenital amegakaryocytic thrombocytopenia identifies a polymorphism. Blood. 2001;97(11):3675\u20133676.","journal-title":"Blood."},{"issue":"12","key":"218_CR69","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/ajh.25275","volume":"93","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501\u20131508.","journal-title":"Am J Hematol."},{"issue":"21","key":"218_CR70","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood.V124.21.5006.5006","volume":"124","author":"H Rosenbaum","year":"2014","unstructured":"Rosenbaum H. Novel management of immune thrombocytopenia in Gaucher disease patients. Blood. 2014;124(21):5006.","journal-title":"Blood."},{"issue":"1","key":"218_CR71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.2004.04987.x","volume":"126","author":"C Briggs","year":"2004","unstructured":"Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126(1):93\u201399.","journal-title":"Br J Haematol."},{"issue":"7","key":"218_CR72","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","volume":"99","author":"RL Basser","year":"2002","unstructured":"Basser RL, O\u2019Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99(7):2599\u20132602.","journal-title":"Blood."},{"issue":"1","key":"218_CR73","doi-asserted-by":"publisher","first-page":"2492925","DOI":"10.1080\/16078454.2025.2492925","volume":"30","author":"L Chen","year":"2025","unstructured":"Chen L, Fang L, Kuang Z, et al. Cost utility analysis of adult patients with severe aplastic anemia: a single-center study. Hematology. 2025;30(1):2492925.","journal-title":"Hematology."},{"issue":"9","key":"218_CR74","first-page":"666.e1","volume":"31","author":"F Luo","year":"2025","unstructured":"Luo F, Luo Z, Luo Y, et al. Herombopag versus rhTPO in stem cell transplantation: a comparative study of efficacy, safety, and cost-effectiveness. Transplant Cell Ther. 2025;31(9):666.e1\u2013666.e4.","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"218_CR75","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/bjh.19161","volume":"203","author":"A Rottenstreich","year":"2023","unstructured":"Rottenstreich A, Bussel JB. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. Br J Haematol. 2023;203(5):872\u2013885.","journal-title":"Br J Haematol."},{"issue":"1","key":"218_CR76","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s12884-023-06134-y","volume":"23","author":"J Lin","year":"2023","unstructured":"Lin J, Wang TF, Huang MJ, et al. Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study. BMC Pregnancy Childbirth. 2023;23(1):820.","journal-title":"BMC Pregnancy Childbirth."},{"issue":"23","key":"218_CR77","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia.\u00a0Blood Adv. 2019;3(23):3829\u20133866.","journal-title":"Blood Adv."},{"issue":"6","key":"218_CR78","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14656566.2023.2198089","volume":"24","author":"T Li","year":"2023","unstructured":"Li T, Liu Q, Pu T, et al. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother. 2023;24(6):763\u2013774.","journal-title":"Expert Opin Pharmacother."},{"issue":"13","key":"218_CR79","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1080\/14656566.2025.2557448","volume":"26","author":"LE Merz","year":"2025","unstructured":"Merz LE, Fogerty AE. Treatment options for immune thrombocytopenia (ITP) in pregnancy and postpartum. Expert Opin Pharmacother. 2025;26(13):1441\u20131449.","journal-title":"Expert Opin Pharmacother."},{"issue":"9","key":"218_CR80","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17474086.2024.2385481","volume":"17","author":"M Beltrami-Moreira","year":"2024","unstructured":"Beltrami-Moreira M, Sharma A, Bussel JB. Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management. Expert Rev Hematol. 2024;17(9):595\u2013607.","journal-title":"Expert Rev Hematol."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-026-00218-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:11:09Z","timestamp":1787584269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-026-00218-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1007\/s11596-026-00218-4","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}